Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19

BACKGROUND: We aimed to evaluate the antiviral activity and safety of darunavir/cobicistat (DRV/c) in treating COVID-19 patients. METHODS: In this single-center, randomized, and open-label trial, mild patients with polymerase chain reaction (PCR)–confirmed COVID-19 were enrolled in Shanghai, China....

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Open Forum Infect Dis
Main Authors: Chen, Jun, Xia, Lu, Liu, Li, Xu, Qingnian, Ling, Yun, Huang, Dan, Huang, Wei, Song, Shuli, Xu, Shuibao, Shen, Yingzhong, Lu, Hongzhou
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2020
Teme:
Major Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7337805/
https://ncbi.nlm.nih.gov/pubmed/32671131
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofaa241
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki